Group sales came in at EUR 10.7B vs. EUR 11.1B last year. EBITDA before special items was EUR 2.1B vs. EUR 2.1B last year. Group EBIT came in at EUR 13M vs. EUR 525M last year. Net income amounted to (EUR 199M) vs. (EUR 34M) last year. Free cash flow was EUR 125M vs. EUR 1.27B last year. Net financial debt at EUR 33.27B. “We’re beginning an important second half of 2025, which will be marked by further progress on all strategic priorities, continued launches, and geopolitical and currency crosswinds to navigate,” CEO Bill Anderson said. “Thanks to our year-to-date performance in Pharmaceuticals, we’re raising our 2025 currency-adjusted guidance for the Group on both sales and earnings.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer’s New Study on Sevabertinib: A Potential Game-Changer for Cancer Patients with Liver Impairment
- Bayer’s SMART-Finder Study: A Closer Look at T2DM and Kidney Health
- Bayer’s FINEROD Study: Evaluating Finerenone in Real-World Settings
- Bayer AG’s Real-World Study on Hemophilia A Treatment: Market Insights
- Bayer’s Observational Study on Darolutamide: Real-World Insights for Prostate Cancer Treatment